Neogen Co. (NASDAQ:NEOG) Shares Purchased by Values First Advisors Inc.

Values First Advisors Inc. lifted its position in Neogen Co. (NASDAQ:NEOG) by 6.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,137 shares of the company’s stock after acquiring an additional 896 shares during the period. Values First Advisors Inc.’s holdings in Neogen were worth $304,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in NEOG. Raymond James Trust N.A. grew its holdings in shares of Neogen by 6.7% during the 1st quarter. Raymond James Trust N.A. now owns 6,981 shares of the company’s stock worth $215,000 after purchasing an additional 441 shares during the period. United Services Automobile Association grew its holdings in shares of Neogen by 4.5% during the 2nd quarter. United Services Automobile Association now owns 13,988 shares of the company’s stock worth $304,000 after purchasing an additional 608 shares during the period. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Neogen by 5.8% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 12,900 shares of the company’s stock worth $259,000 after purchasing an additional 711 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Neogen by 1.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 40,163 shares of the company’s stock valued at $968,000 after acquiring an additional 759 shares during the period. Finally, Simmons Bank boosted its holdings in Neogen by 4.1% during the 3rd quarter. Simmons Bank now owns 19,740 shares of the company’s stock valued at $366,000 after acquiring an additional 775 shares during the period. 96.73% of the stock is currently owned by hedge funds and other institutional investors.

Neogen Stock Up 2.1 %

NEOG stock traded up $0.32 during mid-day trading on Thursday, reaching $15.78. The company had a trading volume of 1,275,580 shares, compared to its average volume of 1,877,231. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.63 and a current ratio of 3.54. The company has a market capitalization of $3.42 billion, a price-to-earnings ratio of 264.21 and a beta of 1.14. The firm has a fifty day simple moving average of $16.32 and a 200 day simple moving average of $17.21. Neogen Co. has a fifty-two week low of $14.44 and a fifty-two week high of $24.09.

Neogen (NASDAQ:NEOG) last released its quarterly earnings data on Tuesday, January 9th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.08. Neogen had a net margin of 1.28% and a return on equity of 3.35%. The business had revenue of $229.60 million during the quarter, compared to analysts’ expectations of $232.85 million. During the same period in the previous year, the company earned $0.15 EPS. The company’s revenue for the quarter was down .2% on a year-over-year basis. Analysts forecast that Neogen Co. will post 0.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Piper Sandler raised their target price on Neogen from $17.50 to $19.00 and gave the company a “neutral” rating in a report on Thursday, January 18th.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.